S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
LON:DXRX

Diaceutics (DXRX) Share Forecast, Price & News

GBX 105
0.00 (0.00%)
(As of 09/29/2023 07:39 PM ET)
Compare
Today's Range
103.80
107
50-Day Range
87.50
109
52-Week Range
74
118
Volume
15,650 shs
Average Volume
56,104 shs
Market Capitalization
£88.69 million
P/E Ratio
10,500.00
Dividend Yield
N/A
Price Target
GBX 150

Diaceutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.9% Upside
GBX 150 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Diaceutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
£139 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars


DXRX stock logo

About Diaceutics (LON:DXRX) Stock

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

DXRX Price History

DXRX Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Diaceutics PLC (DXRX.L)
Is this FTSE AIM stock primed for growth in 2022?
See More Headlines
Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Phone
N/A
Fax
N/A
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 150
High Stock Price Forecast
GBX 150
Low Stock Price Forecast
GBX 150
Forecasted Upside/Downside
+42.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21.90 million
Cash Flow
GBX 33.66 per share
Book Value
GBX 49 per share

Miscellaneous

Free Float
N/A
Market Cap
£88.69 million
Optionable
Not Optionable
Beta
0.36
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Peter Keeling (Age 61)
    Founder, CEO & Exec. Director
    Comp: $363.24k
  • Mr. Nicholas Stewart Roberts (Age 40)
    CFO & Director
    Comp: $180.37k
  • Mr. Ryan Keeling (Age 40)
    Chief Innovation Officer & Exec. Director
    Comp: $334.27k
  • Ms. Julie Browne
    Chief Operating Officer
  • Ms. Gillian Shaw
    Gen. Counsel
  • Ms. Jillian Beggs
    VP of Sales & Marketing
  • Ms. Norma Thompson
    Global Head of HR
  • Mr. Jordan Clark
    Chief Commercial Officer
  • Ms. Susanne Munksted
    Chief Precision Medicine Officer
  • Ms. Marieke Hoefsmit
    Sr. Director & Head of Data Delivery Netherlands













DXRX Stock - Frequently Asked Questions

Should I buy or sell Diaceutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DXRX shares.
View DXRX analyst ratings
or view top-rated stocks.

What is Diaceutics' stock price forecast for 2023?

2 analysts have issued 12 month target prices for Diaceutics' stock. Their DXRX share price forecasts range from GBX 150 to GBX 150. On average, they predict the company's stock price to reach GBX 150 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price.
View analysts price targets for DXRX
or view top-rated stocks among Wall Street analysts.

How have DXRX shares performed in 2023?

Diaceutics' stock was trading at GBX 75.50 at the beginning of the year. Since then, DXRX stock has increased by 39.1% and is now trading at GBX 105.
View the best growth stocks for 2023 here
.

What is Diaceutics' stock symbol?

Diaceutics trades on the London Stock Exchange (LON) under the ticker symbol "DXRX."

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Diaceutics' stock price today?

One share of DXRX stock can currently be purchased for approximately GBX 105.

How much money does Diaceutics make?

Diaceutics (LON:DXRX) has a market capitalization of £88.69 million and generates £21.90 million in revenue each year.

How many employees does Diaceutics have?

The company employs 151 workers across the globe.

This page (LON:DXRX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -